Integra LifeSciences | Sustainability Performance
Develops and markets medical devices and regenerative technologies for use in neurosurgery, reconstructive surgery, orthopedics, and wound care. Its portfolio includes implants, biomaterials, and instruments, distributed globally through direct sales channels and partnerships with healthcare systems and hospitals.
1989
United States
1,001 - 5,000 employees
Medical Device
$1B - 10B in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#8559
Overallⓘ#1973
in United Statesⓘ#136
in Medical DeviceⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Integra LifeSciences Holdings Corporation, US medical devices (regenerative tissue, neurosurgery), has faced multiple US FDA enforcement actions including the historic 2023 USD 145 million Boston Scientific Bostrol product liability legacy and the contested 2024 sustained scrutiny over Integra Acclarent ENT product safety affecting US institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.